Thursday, 7 June 2018

36. Drug trial for aggressive breast cancer and hormone therapy




Approximately 10–15 per cent of breast cancer tumours do not respond to treatment with standard hormone therapy, which means that they are more aggressive and often recur.
An international research team led by Professor Kristian Pietras at Lund University, Sweden, has uncovered a way to treat these aggressive tumours through manipulation of the connective tissue cells of the breast cancer.
“Previously, it was believed that the various subgroups of breast cancer originated from different cell types in the mammary gland. Our research has shown that connective tissue cells can also modify tumour cells directly with regard to their sensitivity to hormones, which has significant implications in the development of more effective treatments”, states Professor Ulf Eriksson of Stockholm’s Karolinski Institute, who collaborated in the study.
The researchers tested a new biological drug they developed which blocked the PDGF-CC-mediated communication between the tumour cells and the connective tissue cells. This resulted in the transformation of the basal breast cancers into hormone-sensitive luminal breast cancers that were highly responsive to conventional hormone therapy.
“We have thus developed a new treatment strategy for aggressive and difficult-to-treat breast cancers that restores sensitivity to hormone therapy. These findings have major implications in the development of more effective treatments for patients with aggressive breast cancer”, concludes Kristian Pietras.
Following this study, the researchers are developing a new drug for trial which will transform aggressive breast cancer tumour so that they respond to standard hormone therapy.

Filed 26.03.2018. Caring Cancer Trust

35. Multi-targeted immunotherapy trial in Childhood Leukaemia


Lymphoblasts from an ALL patient stained in blue. Photo courtesy of Nirali Shah
Following news of a phase 3 trial of AstraZeneca’s experimental drug (In The News 23.03.18), we are notified of a new phase 1 clinical trial being conducted at Bethesda Hospital, Maryland, for acute lymphoblastic leukemia (ALL) treatment. It will use a double-barrelled approach that targets two proteins found on the surface of the cancer cells.
In ALL the bone marrow makes abnormally high levels of immature white blood cells called lymphoblasts. Using chimeric antigen receptor (CAR) T cells to attack Cancer cells has shown promise as an emerging ALL treatment and will be the approach used in this new trial.
In this trial therapy, headed by Nirali Shah M.D., of the US National Cancer Institute, CAR T cells—white blood cells that defend the body against disease—are collected from patients and engineered in the laboratory to express receptors that target the two specific proteins on the surface of cancer cells. The collected CAR T cells are prodded to proliferate in the clinic and then infused back into patients. The clinicians expect that these cells will further proliferate in the body, hone in on the cancer cells bearing the surface protein target and kill them.
70 - 90% of ‘ALL’ patients who have relapsed or become resistant to chemotherapy can achieve remission of their disease after receiving CAR T-cell therapy that targets a protein found on the surface of lymphoblasts. But 30 - 50% of these patients suffer a further relapse.
Success in this strategy of targeting two proteins simultaneously will bring CAR T-cell therapy closer to durable remission in the most common of childhood Cancers.

Filed 16 April, 2018, Caring Cancer Trust

34. Genomic Differences between Childhood and Adult Cancers



A recent pan-cancer study in USA published in Nature, 28 February, has found that several cancer types are genetically different in children and adults.
The paediatric study, led by Jinghui Zhang, Ph.D., at St. Jude Children's Research Hospital, Memphis, analysed samples from nearly 1,700 patients, aged 20 or younger, looking at all non-inherited, or somatic, genetic alterations. Adult patients in the TARGET study elsewhere in USA had common childhood cancers, including acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), neuroblastoma, Wilms tumour, and osteosarcoma.
The researchers identified 142 altered genes that drive the development of these cancers (driver mutations), of which only 45% are found in adult cancers.
The findings reinforce the growing belief that drugs developed and approved to treat cancers in adults may not always be effective or appropriate for children with the same cancer types, emphasising the need for paediatric cancer-specific development of precision therapies.
Further Reading
Nature, International Journal of Science.

Filed 24 April, Caring Cancer Trust.